Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-Month Phase 2 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

Next Previous
Trial Profile

A 3-Month Phase 2 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tildacerfont (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Adverse reactions
  • Sponsors Spruce Biosciences

    • Most Recent Events

    • 19 Sep 2019 According to a Spruce Biosciences media release, Richard Auchus (M.D., Ph.D.) is an investigator in this study and professor of internal medicine and pharmacology, division of metabolism, endocrinology and diabetes at University of Michigan, Ann Arbor.
    • 19 Sep 2019 According to a Spruce Biosciences media release, full results of the study will be reported at an upcoming medical conference.
    • 19 Sep 2019 Results presented in a Spruce Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top